ALVO (Alvotech SA) Enterprise Value-to-Revenue Ratio

Public company logo of alvotech.com (ALVO)

Alvotech aims for global dominance in the affordable biosimilars segment. The primary growth potential lies in scalability: following massive R&D expenditures, the production of blockbuster copies ensures colossal profitability. Opening the EV/Sales business valuation level on GURU.Markets, we observe that the 6191.19 mark records this metric. This confirms the impact of drug launches in the US and Europe, which rely on Icelandic production.

Alvotech S.A. (ALVO): Company Value to Revenue from 11/23/2025 to 11/20/2026

Alvotech Biopharmaceuticals - analytical breakdowns and key metrics (ALVO)

- share price and expert price forecast:
Fundamental company valuation:Alvotech ALVO
Core merchandise of Alvotech Corp

The EV/Sales ratio determines the value of the entire business relative to its operating revenue, excluding the impact of debt load to reveal the asset's true market valuation. By analyzing EV/Sales dynamics, an investor can see the extent to which the market is willing to pay a premium for the complex technological capabilities of Alvotech (ALVO) and its ability to overcome patent barriers in the biosimilars segment, allowing for an objective assessment of the company's value.

Competitor analysis for Alvotech

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple LQDA (Liquidia Technologies)|EV/Sales Multiple Galapagos GLPG|ANI Pharmaceuticals Inc - EV/Sales Multiple|MNKD (MannKind Corp.) - Company Value to Revenue Ratio|AMPH: EV/Sales Multiple|PCRX (Pacira BioSciences) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio